Just months after Immune Design triggered an exodus of investors with news of a Phase II setback on its leading immuno-oncology work, Merck has stepped up to buy the company and plug it into its immunology group.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,100+ biopharma pros who read Endpoints News by email every day.Free Subscription